Schmitz N
Second Department of Internal Medicine, Christian-Albrechts-Universitat, Kiel, Germany.
Nouv Rev Fr Hematol (1978). 1995;37(6):377-9.
Transplantation of autologous peripheral blood progenitor cells (PBPC) is now a well established method to reconstitute haematopoiesis after high-dose chemoradiotherapy. Allogeneic PBPCs have rarely been used as the sole measure to induce haematopoietic recovery after myeloablative therapy because of uncertainties regarding the durability of engraftment and the risk of acute and chronic graft-vs-host disease (GVHD). In addition, this technique requires the exposure of normal donors to granulocyte colony stimulating factor (G-CSF) in order to mobilise a sufficient number of PBPCs which can then be collected by leukapheresis. We report here our initial experience with allogeneic transplantation of PBPCs in order to demonstrate the feasibility and safety of harvesting sufficient numbers of PBPCs in healty donors. In addition, the early results presented in this communication show that allogeneic PBPCs can successfully be used to restore haematopoiesis in HLA-identical siblings of the donor without causing devastating graft-vs-host disease.
自体外周血祖细胞（PBPC）移植如今是一种在大剂量放化疗后重建造血功能的成熟方法。由于植入的持久性存在不确定性以及急性和慢性移植物抗宿主病（GVHD）的风险，异基因PBPC很少被用作清髓治疗后诱导造血恢复的唯一措施。此外，该技术要求正常供体接受粒细胞集落刺激因子（G-CSF），以动员足够数量的PBPC，然后通过白细胞分离术进行采集。我们在此报告我们异基因PBPC移植的初步经验，以证明在健康供体中采集足够数量PBPC的可行性和安全性。此外，本通讯中展示的早期结果表明，异基因PBPC可成功用于恢复供体 HLA 相同的同胞的造血功能，而不会引发严重的移植物抗宿主病。
